Swiss National Bank Sells 31,400 Shares of Amylyx Pharmaceuticals, Inc. $AMLX

Swiss National Bank trimmed its holdings in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 19.4% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 130,300 shares of the company’s stock after selling 31,400 shares during the period. Swiss National Bank owned approximately 0.12% of Amylyx Pharmaceuticals worth $1,811,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. increased its stake in shares of Amylyx Pharmaceuticals by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock valued at $56,408,000 after acquiring an additional 3,102,395 shares in the last quarter. Millennium Management LLC boosted its stake in Amylyx Pharmaceuticals by 418.6% during the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock worth $10,910,000 after acquiring an additional 2,487,617 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Amylyx Pharmaceuticals by 76.1% during the fourth quarter. Janus Henderson Group PLC now owns 4,465,872 shares of the company’s stock worth $53,992,000 after acquiring an additional 1,929,639 shares in the last quarter. Paradigm Biocapital Advisors LP acquired a new stake in Amylyx Pharmaceuticals in the third quarter worth $25,821,000. Finally, Commodore Capital LP grew its holdings in Amylyx Pharmaceuticals by 38.6% in the fourth quarter. Commodore Capital LP now owns 5,650,000 shares of the company’s stock worth $68,252,000 after purchasing an additional 1,574,522 shares during the period. Institutional investors and hedge funds own 95.84% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on AMLX. HC Wainwright reiterated a “buy” rating and set a $34.00 price objective on shares of Amylyx Pharmaceuticals in a report on Monday, June 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Friday, May 8th. Mizuho boosted their target price on Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the company an “outperform” rating in a research report on Monday, July 20th. Wall Street Zen downgraded Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Guggenheim increased their price target on Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $24.62.

Insiders Place Their Bets

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of Amylyx Pharmaceuticals stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the completion of the transaction, the insider owned 194,090 shares in the company, valued at approximately $3,555,728.80. The trade was a 7.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.90% of the company’s stock.

Amylyx Pharmaceuticals Trading Up 5.2%

AMLX opened at $20.75 on Friday. The company’s fifty day moving average price is $16.41 and its two-hundred day moving average price is $15.41. Amylyx Pharmaceuticals, Inc. has a 1-year low of $7.48 and a 1-year high of $20.94. The company has a market cap of $2.31 billion, a price-to-earnings ratio of -13.83 and a beta of -0.20.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). As a group, equities analysts forecast that Amylyx Pharmaceuticals, Inc. will post -1.4 earnings per share for the current fiscal year.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.